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Abstract 
One of the hallmarks of Alzheimer’s disease (AD) in the brain are amyloid- 
(A) plaques, and metal ions such as copper(II) and zinc(II) have been shown to play a 
role in the aggregation and toxicity of the A peptide, the major constituent of these 
extracellular aggregates. Metal binding agents can promote the disaggregation of A 
plaques, and have shown promise as AD therapeutics. Herein, we describe the syntheses 
and characterization of an acetohydrazone (8-H2QH), a thiosemicarbazone (8-H2QT), 
and a semicarbazone (8-H2QS) derived from 8-hydroxyquinoline. The three compounds 
are shown to be neutral at pH 7.4, and are potent antioxidants as measured by a Trolox 
Equivalent Antioxidant Capacity (TEAC) assay. The ligands form complexes with Cu
II
, 
8-H2QT in a 1:1 metal:ligand ratio, and 8-H2QH and 8-H2QS in a 1:2 metal:ligand ratio. 
A preliminary aggregation inhibition assay using the Aβ1-40 peptide showed that 8-H2QS 
and 8-H2QH inhibit peptide aggregation in the presence of Cu
II
. Native gel 
electrophoresis/Western blot and TEM images were obtained to give a more detailed 
picture of the extent and pathways of A aggregation using the more neurotoxic A 
in the presence and absence of Cu
II
, 8-H2QH, 8-H2QS and the drug candidate PBT2. An 
increase in the formation of oligomeric species is evident in the presence of Cu
II
. 
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However, in the presence of ligands and Cu
II
, the results match those for the peptide 
alone, suggesting that the ligands function by sequestering Cu
II
 and limiting oligomer 
formation in this assay.  
Keywords: 8-hydroxyquinoline; Copper (II) complex; Alzheimer’s disease. 
Note: Luiza M. F. Gomes and Rafael P. Vieira contributed equally to this work. 
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1. Introduction 1 
 Dementias are progressive pathophysiological disorders characterized by 2 
neuronal cell loss and severe cognitive impairment.
1-3
 The higher prevalence of these 3 
neurodegenerative processes in the elderly, and the increased life expectancy in many 4 
countries, represents a significant burden on healthcare systems around the globe.  5 
There are over 35 million people worldwide displaying dementia symptoms and this 6 
number is expected to double by 2030 (65.7 million) and more than triple by 2050 7 
(115.4 million).
2, 4-5
 Alzheimer’s Disease (AD) is the most common type of dementia 8 
and is characterized by oxidative stress, misfolded proteins, neuronal cell loss, and 9 
eventually death.
2, 6-7
 The mechanism underlying the causes and progression of AD is 10 
subject to enormous research efforts, and the search for new and effective therapies is 11 
justified by the lack of effective treatment options.
8-9
  12 
 Diagnosis of AD, as opposed to other forms of dementia, requires post-mortem 13 
examination of the brain to determine the severity of neuropathological hallmarks of the 14 
disease; amyloid-beta (A) plaques and neurofibrillary tangles. Neurofibrillary tangles 15 
are intracellular fibrillar aggregates of oxidatively-modified and hyperphosphorylated 16 
microtubule-associated protein tau.
10
 A-plaques are extracellular deposits of fibrils and 17 
amorphous aggregates of the A peptide (vide infra). The amyloid hypothesis has long 18 
been the dominant theory to explain the cause of AD, postulating that A plaque 19 
depositions, or partially aggregated soluble A, trigger a neurotoxic cascade causing 20 
AD pathology.
11-13
 Soluble forms of Aβ better correlate with memory impairment and 21 
AD progression in comparison to A plaques,14 however, nearly all aggregated forms 22 
exhibit toxicity. Metal ions, such as Cu
II
, Zn
II
 and Fe
III
 exhibit a relatively high binding 23 
affinity with the A peptide,15-18 and this process can modulate aggregation,19-21 induce 24 
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the formation toxic oligomers and reactive oxygen species (ROS) leading to oxidative 25 
stress.
22-23
 A plaques are the most prominent pathological feature of AD, however 26 
soluble oligomeric forms of the peptide (approximately 1% of total Ain brainhave 27 
been found to show a better correlation with disease progression.
14, 24-25
 When Zn
II
 binds 28 
to A there is an increase in the formation of non-fibrillar aggregates22, 26 without 29 
causing an oxidative cascade, whereas the Cu
II 
- Ainteraction generates non-fibrillar 30 
aggregates (oligomer stabilization)
22, 27-29
 and oxidative damage likely via ROS 31 
generation.
30
 Cellular toxicity studies in  neuroblastoma cell lines have shown that Zn
II
 32 
reduces A1-42 toxicity, while Cu
II
 significantly increases A1-42 neurotoxicity.
22
 For 33 
these reasons, despite the fact that both Cu
II
 and Zn
II
 precipitate A, it has been 34 
postulated that the Zn
II
 - A interaction exhibits an overall protective effect in the 35 
brain.
26, 30
 We have thus chosen to focus on modulating the Cu
II
 - A interaction in this 36 
work. 37 
 The development of metal-protein attenuating compounds (MPAC) is a 38 
promising therapeutic approach for AD treatment. Targeting the metal-Ainteraction in 39 
the extracellular environment could normalize the distribution of both metal ions and 40 
Apeptide in brain tissue and cerebrospinal fluid.24, 31-34 Clioquinol (5-chloro-7-iodo-8-41 
hydroxyquinoline, HCQ, Fig. 1) is a small, lipophilic and bioavailable metal chelator, 42 
with high selectivity for Zn
II
 and Cu
II
, that has been reported to cross the BBB 43 
efficiently in the Tg2576 mouse model.
4, 35
 HCQ is the archetypical MPAC, and has 44 
shown promise as an AD therapeutic in both animal models and preliminary clinical 45 
trials.
2, 35-36
 A second generation 8-hydroxyquinoline derivative, PBT2 (Fig. 1), 46 
demonstrated therapeutic potential in AD murine models,
37-38
 and Phase II clinical 47 
studies.
39-40
 This compound has been shown to reduce A aggregation, limit A 48 
oligomer toxicity, and redistribute metal ions (Cu
II
 and Zn
II
) into neurons.
2, 34
 A number 49 
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of other chemical scaffolds have shown promise as prototype MPAC’s for AD therapy.9, 50 
29, 41-48
 In this work we have studied Schiff-bases derived from 8-hydroxy-2-51 
quinolincarboxaldehyde as new MPAC for AD therapy. Hydrazones, semicarbazones 52 
and thiosemicarbazones are Schiff-bases that have shown broad pharmacological 53 
application and their mechanisms of action frequently involve metal-chelating 54 
properties in vivo.
49
 Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) is 55 
a promising Schiff base that is currently being investigated in several Phase II clinical 56 
trials for cancer therapy; whose pharmacological activity involves iron chelation.
50-54
 57 
Furthermore, it has shown effectiveness in preventing or reducing ROS accumulation 58 
and the concomitant oxidative damage in both AD-derived and age-matched olfactory 59 
neuroepithelial cells.
55
 60 
 61 
Insert Fig. 1 62 
Herein, we have studied the Schiff base compounds 2-[(8-63 
Hydroxyquinolinyl)methylene]acetohydrazide (8-H2QH), 2-[(8-64 
Hydroxyquinolinyl)methylene]hydrazinecarboxamide (8-H2QS), and 2-[(8-65 
Hydroxyquinolinyl)methylene]hydrazinecarbothioamide
56
 (8-H2QT) where H2L stands 66 
for the neutral compound (Fig. 1). These compounds can bind transition metals in 67 
bidentate, tridentate or tetradentate coordination modes.
56-58
 The characterization of the 68 
Cu
II
 chelation and A interaction properties of 8-H2QH and 8-H2QS are reported along 69 
with the evaluation of their ability to modulate A aggregation. 70 
2. Experimental 71 
All common chemicals were purchased from Aldrich and used without further 72 
purification. The syntheses of the ligands 2-[(8-73 
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Hydroxyquinolinyl)methylene]acetohydrazide (8-H2QH), 2-[(8-74 
Hydroxyquinolinyl)methylene]hydrazinecarboxamide (8-H2QS), 2-[(8-75 
Hydroxyquinolinyl)methylene]hydrazinecarbothioamide (8-H2QT),  and their Cu
II
 76 
complexes were performed using previously described methodologies.
56-57
 PBT2 was 77 
synthesized according to a reported method.
59
 The ligand 8-H2QS was previously 78 
obtained in its hydrochloride form,
58
 herein the neutral form was prepared. The Cu
II
 79 
complex of 8-H2QT (Cu(8-QT)) was synthesized as reported.
57
 The A1–40 and A1–42 80 
peptides were purchased from 21st Century Biochemicals (Marlborough, MA, USA). 81 
The 10-20% Tris-tricine mini gels were purchased from BioRad and membranes from 82 
PALL – Life Sciences. 1H and 13C NMR spectra were recorded on a Bruker AV-600 83 
instrument. Mass spectra (positive ion) were obtained on an Agilent 6210 time-of-flight 84 
electrospray ionization mass spectrometer. Electronic spectra were obtained on a Cary 85 
5000 spectrophotometer. Magnetic susceptibilities were measured on a Johnson 86 
Matthey MSB/AUTO balance. Elemental analyses were performed on a Perkin Elmer 87 
CHN 2400 analyzer. A YSI model 31 conductivity bridge was employed for molar 88 
conductivity measurements. Infrared spectra were recorded on a Perkin Elmer FT-IR 89 
Spectrum GX spectrometer using KBr plates (4000 – 400 cm-1) and CsI/nujol (600 – 90 
200 cm
-1
).  91 
2.1. Synthesis of 2-[(8-Hydroxyquinolinyl)methylene]acetohydrazide (8-H2QH) 92 
8-hydroxy-2-quinolincarboxaldehyde (0.173 g, 1 mmol) was suspended in ethanol 93 
(10 mL) and treated with an excess of acethydrazide (0.081 g, 1.1 mmol). The reaction 94 
mixture was subsequently refluxed for 4 h. The light yellow precipitate that formed was 95 
washed with water, ethanol and diethyl ether, air-dried and isolated in good yield (89%) 96 
and purity. Mp: 224.1 – 225.1 °C. Elemental Found (calcd) for C12H11N3O2: C, 62.83 97 
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(62.87); H 4.95 (4.84); N 18.26 (18.33). 
1
H NMR (DMSO-d6):  11.75 (Enol), 11.68 98 
(Keto) (s,1H); 9.83 (Keto),  9.81 (Enol) (s,1H); 8.35 (Enol), 8.22 (Keto) (s, 1H); 8.32 – 99 
8.29 (Enol and keto) (m, 1H); 8.02 (Enol and keto) (app dd, 1H); 7.45 – 7.37 (Enol and 100 
keto) (m, 2H); 7.13 – 7.10 (Enol and keto) (m, 1H); 2.28 (Keto), 2.02 (Enol) (s, 3H), 101 
13
C NMR (DMSO-d6): 172.4 (Keto), 166.0 (Enol) (C); 153.4 (Enol and keto) (C), 102 
151.8 (Enol), 151.5 (Keto) (C); 145.8 (Enol), 143.1 (Keto) (CH); 138.1 (Enol and keto) 103 
(C); 136.5 (Enol and Keto) (CH); 128.8 (Enol), 128.7 (Keto) (CH); 128.2 (Enol), 128.1 104 
(Keto) (C); 117.8 (Enol and keto) (CH); 117.6 (Enol), 117.3 (Keto) (CH); 112.2 (Enol), 105 
112.1 (Keto) (CH); 21.8 (Enol), 20.3 (Keto) (CH). IR (KBr): (OH) 2928, (CO) 1678, 106 
(CNim) 1594, (CNqui) 1632, (qui) 720 cm
-1
. Suitable crystals for X-ray 107 
crystallography were grown by evaporation of an ethanol solution of 8-H2QH.  108 
2.2. Synthesis of 2-[(8-Hydroxyquinolinyl)methylene]hydrazinecarboxamide (8-109 
H2QS) 110 
This compound has been previously synthesized as the hydrochloride salt.
58
 111 
Semicarbazide hydrochloride (0.123 g, 1.1 mmol) was dissolved in water (10 mL) and 112 
treated with an equivalent of sodium acetate (0.090 g, 1.1 mmol). A suspension of 8-113 
hydroxy-2-quinolincarboxaldehyde (0.173 g, 1 mmol) in ethanol (10 mL) was added 114 
and the reaction mixture was refluxed for 4 h. The light yellow precipitate that formed 115 
was washed with water, ethanol and ether, air-dried and isolated in good yield (95%) 116 
and purity. Mp: 229.7 – 230.1 °C. Elemental Found (calcd) for C11H10N4O2: C, 57.74 117 
(57.39); H 4.32 (4.38); N 23.87 (24.34). 
1
H NMR (DMSO-d6):  10.73 (s, 1H), 9.72 (s, 118 
1H), 8.33 (d, J = 8.7 Hz, 1H), 8.25 (d, J = 8.7 Hz, 1H), 8.08 (s, 1H), 7.42 – 7.35 (m, 119 
2H), 7.08 (dd, J = 1.4, 7.4 Hz, 1H), 6.74 (br s, 2H), 
13
C NMR (DMSO-d6): 156.5 (C), 120 
153.2 (C), 152.2 (C), 139.8 (CH), 137.9 (C), 136.0 (CH), 128.5 (C), 127.7 (CH), 118.1 121 
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(CH), 117.7 (CH), 111.9 (CH). IR (KBr): (OH) 3152, (CO) 1720, (CNim) 1572, 122 
(CNqui) 1578, (qui) 722 cm
-1
. 123 
2.3. Synthesis of copper complexes 124 
2.3.1. Bis{2-[(8-Hydroxyquinolinyl)methylene]acetohydrazide}copper(II) Cu(8-125 
HQH)2 126 
2-[(8-Hydroxyquinolinyl)methylene]acetohydrazide (0.344 g, 1.5 mmol)  was dissolved 127 
in DMF (5 mL) and treated with an excess (0.359 g, 1.8 mmol) of [Cu(OAc)2]·2H2O. 128 
The reaction darkened considerably whilst stirring at room temperature for 4 h. Upon 129 
addition of water (5–10 mL) a solid precipitate was collected, washed repeatedly with 130 
water (3 x 5 mL) and dried in vacuo to afford a dark red solid (90 %). Elemental Found 131 
(calcd) for C24H20N6O4Cu0.5H2O: C, 54.89 (54.49); H, 4.01 (4.00); N, 15.86 (15.89). 132 
IR (KBr): (CO) 1674, (CNim) 1586, (CNqui) 1596, (qui) 746, (MO) 540, (MN) 133 
345 cm
-1
. Effective magnetic moment = 1.66 (BM). MS (ES
+
): m/z (calcd) 521.1011 134 
(521.0140) [M + H
+
]. 135 
2.3.2. Bis{2-[(8-Hydroxyquinolinyl)methylene]hydrazinecarboxamide}copper(II) 136 
Cu(8-HQS)2 137 
The reaction was carried out in a similar manner to Cu(8-HQH)2 to afford a light green 138 
solid of Cu(8-HQS)2 (99 %). Elemental Found (calcd) for C22H18N8O4Cu0.5H2O: C, 139 
50.04 (49.76); H, 3.64 (3.61); N, 20.93 (21.10). IR (KBr): (CO) 1666, (CNim) 1578, 140 
(CNqui) 1556, (qui) 756, (MO) 530, (MN) 476 cm
-1
. Effective magnetic moment = 141 
1.89 (BM). MS (ES
+
): m/z (calcd) 523.0929 (522.9890) [M + H
+
].  142 
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2.3. Crystal structure determination 143 
Single-crystal X-ray diffraction measurements of 8-H2QH were carried out on a 144 
GEMINI-Ultra diffractometer (LabCri-UFMG) using graphite-Enhance Source Mo Kα 145 
radiation (λ=0.71073 Å) at 150 K. Data collection, cell refinement results, and data 146 
reduction were performed using the CRYSALISPRO software.
60
 The semi-empirical 147 
from equivalents absorption correction method was applied.
60
 The structure was solved 148 
by direct methods using SHELXS-97. Full-matrix least-squares refinement procedure 149 
on F
2
 with anisotropic thermal parameters was carried out using SHELXL-97.
61
 150 
Positional and anisotropic atomic displacement parameters were refined for all non-151 
hydrogen atoms. Hydrogen atoms were placed geometrically and the positional 152 
parameters were refined using a riding model. A molecular plot and crystal packing 153 
figures were prepared using ORTEP
62
 and MERCURY
63
, respectively. Tables were 154 
generated using WINGX suite.
64
 A summary of the crystal data, data collection details 155 
and refinement results are listed in Table 1. 156 
Insert Table 1 157 
2.4. Metal binding studies 158 
Metal binding studies were performed by varying the molar fractions of CuCl2 from 0 to 159 
1 (0 to 4.0 x 10
-5
 mol L
-1
) in 20% DMSO/HEPES Buffer pH 7.4 in the presence of 160 
ligand to obtain UV-Vis spectra. An absorbance maximum was assigned as interaction 161 
of metal and ligand for each solution, which gave the determination of the metal:ligand 162 
ratio in the complex.  163 
2.5. Calculations 164 
Density functional theory (DFT) calculations were used to obtain optimized geometries 165 
for the doublet states of the Cu(8-HQH)2, Cu(8-HQS)2, Cu(CQ)2, and Cu(8-QT) 166 
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complexes. The Gaussian 09 program (revision D.01)
65
 was used with the B3LYP 167 
functional
66-67
 and the 6-31G(d) basis set on all atoms. Frequency calculations at the 168 
same level of theory confirmed that the optimized structures were located at a minimum 169 
on the potential energy surface.   170 
2.6. Determination of acidity constants by UV-Vis 171 
The speciation of 8-H2QS, 8-H2QT and 8-H2QH at physiological pH were obtained by 172 
the determination of acidity constants through variable pH UV-vis spectra. Solutions of 173 
8-H2QS, 8-H2QT and 8-H2QH (40 M) were prepared in 5% DMSO in 0.1 M NaCl. A 174 
pH electrode was calibrated using a 2-point method (pH 4.01 and 10.01 standard 175 
buffers) before obtaining UV-Vis spectra. The pH of the ligand solutions was increased 176 
by NaOH to a starting point of ca. pH 12. UV-Vis spectra of the ligand solutions were 177 
obtained in the range of 600–190 nm at different pH by addition of aliquots of HCl. At 178 
least 30 UV-vis spectra were obtained in the range of pH 2–12. The HypSpec program 179 
(Protonic Software, UK) was used to analyze spectral data.
68
 HySS2009 program 180 
(Protonic Software, UK) was used to simulate speciation diagrams for 8-H2QS, 8-H2QT 181 
and 8-H2QH.
69
 182 
2.7. Antioxidant capacity – TEAC test 183 
The ability of the 8-hydroxyquinoline derivatives 8-H2QH, 8-H2QS and 8-H2QT to 184 
scavenge free radicals was evaluated using the Trolox Equivalent Antioxidant Capacity 185 
(TEAC) assay.
70
 These compounds were compared to both PBT2 and HCQ. Natural 186 
antioxidants, Vitamin E ((±)--tocopherol) and glutathione, were used as positive 187 
controls. The relative TEAC values were determined by a decolourization assay with 188 
2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) radical cation. ABTS was 189 
dissolved in water (7 mM) and reacted with potassium persulfate (2.45 mM) in the dark 190 
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for 16 h to form the colored ABTS radical cation. This stock solution of ABTS was 191 
diluted with methanol to an absorbance value of 0.70 (± 0.02) at 744 nm. To start the 192 
reaction, solutions of 8-H2QH, 8-H2QS, 8-H2QT, HCQ, and PBT2 in DMSO (20 µL, 193 
3.0-15.0 µM) were added to 2 mL of ABTS solution. The absorbance value was 194 
measured in triplicate for each time point (1, 3, and 6 min). The value of absorbance at 195 
744 nm was plotted as a function of compound concentration. The slopes were then 196 
compared to the standard, trolox (6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic 197 
acid), with its TEAC value normalized to 1.
70-71
  198 
2.8. Turbidity measurements 199 
A 200 M stock solution of lyophilized synthetic human A1–40 (21st Century 200 
Biochemicals) was freshly prepared before each trial was performed. Each vial of 201 
peptide, which contained ca. 0.25 mg A1–40, was dissolved in 290 L of deionized 202 
water. To achieve complete dissolution of the peptide, sonication for 1 minute followed 203 
by a 30 second pause was repeated twice.
9
 A 20 mM HEPES buffer solution containing 204 
150 mM NaCl was prepared and treated with Chelex in deionized water at pH 6.6
72
 and 205 
used to prepare stock solutions of ligands, Cu
II
, and DTPA, as well as the reaction 206 
mixtures in the 96-well plates. The turbidity assay was conducted in quadruplicate in 207 
flat-bottomed 96-well assay plates (Microtest, BD Falcon). Ligands, Cu
II
 and A1–40 208 
peptide had final concentrations of 150 M, 25 M and 25 M, respectively. CuII 209 
solution was prepared from atomic absorption standards (Sigma-Aldrich). Cu
II
, A1–40 210 
and HEPES buffer were first added to the 96-well plate followed by the ligands. The 211 
solutions were incubated for 45 minutes at 37 °C under constant agitation, and each well 212 
in the 96-well plate was measured at 405 nm using a Synergy 4 Fluorometer plate 213 
reader from BioTek. Wells containing ligand, metal and buffer were used as blank and 214 
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subtracted from corresponding wells. Positive controls containing metal and peptide 215 
were used to demonstrate the effect of the absence of ligand on peptide aggregation. 216 
2.9. Native Gel Electrophoresis and Western Blotting 217 
A1-42 was first monomerized using a reported procedure, which includes dissolving 218 
A1-42 (21st Century Biochemicals) in hexafluoroisopropanol (HFIP) (0.5 mM), 219 
sonication for 15 min and incubating overnight at 4°C.
73-74
 The solution was then 220 
aliquoted and evaporated under stream of N2. The monomeric films were stored at -80 221 
°C. The peptide was then dissolved in 1:1 DMSO/ddH2O solution and concentration 222 
was assessed by UV-Vis spectroscopy. The amount of DMSO solvent (2.8%) in the 223 
eventual incubation solution is small, and has been previously shown to have no effect 224 
on fibril growth.
75
 A solutions were then incubated for 24 h at 37 °C with continuous 225 
agitation at 200 rpm to generate fibrils in the presence of ligands, or ligands and Cu
II 
in 226 
0.1M PBS buffer at pH 7.4. A 10 – 20% gradient tris-tricine mini gel was used to 227 
separate samples at 100 V for 100 min at room temperature. The gels were transferred 228 
to a nitrocellulose membrane on an ice bath for 3 hours at 40 V at 4 °C. The membrane 229 
was blocked in a 3% BSA solution in TBS for 1 hour. The membrane was incubated in 230 
a solution (1:2000 dilution) of 6E10 anti-A primary antibody (Covance) overnight at 231 
298 K. After washing 4 X 15 mins with TBS buffer, the membrane was incubated in a 232 
solution containing the secondary antibody (Horseradish peroxidase, Caymen 233 
Chemicals) for 3 hours. Thermo Scientific SuperSignal® West Pico Chemiluminescent 234 
Substrate kit was used to visualize the A species using a FUJIFILM Luminescent 235 
Image Analyzer (LAS-4000). 236 
 237 
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2.10. Transmission Electron Microscopy (TEM) 238 
Samples were prepared from the Western blot assay after the 24 hour incubation time at 239 
37 °C. TEM grids were prepared following previously reported methods.
9,
 
76
 In order to 240 
increase hydrophilicity, the Formvar/Carbon 300-mesh grids (Electron Microscopy 241 
Sciences) were glow discharged in a vacuum for 15 seconds. Drops of samples (10 L) 242 
were placed onto a sheet of parafilm and the TEM grid was laid on the drop for 5 243 
minutes. The grid was then placed on the first drop of syringe-filtered 5% uranyl acetate 244 
and immediately removed, repeated for the second drop, then placed on the third drop to 245 
incubate for 1 minute. Excess uranyl acetate was removed using a tissue between drops. 246 
The grid was allowed to air-dry for at least 15 minutes. Bright field images were 247 
obtained on a Hitachi 8000 STEM with a lanthanum hexaboride thermoionic source 248 
operating at 200 kV and at a magnification of 20000 x. 249 
2.11. Cytotoxic activity 250 
2.11.1. Cell lines 251 
HL60 (wild type human promyelocytic leukemia) and Jurkat (human immortalized line 252 
of T lymphocyte), cell lines were kindly donated by Dr. Gustavo Amarante-Mendes 253 
(Universidade de São Paulo, Brazil).  MDA-MB 231 (human breast carcinoma) line was 254 
kindly provided by Dr. Alfredo Goes (Universidade Federal de Minas Gerais, Brazil). 255 
All lineages were maintained in the logarithmic phase of growth in RPMI 1640 or 256 
DMEM (Dulbecco's Modified Eagle Medium) supplemented with 100 U mL
-1
 penicillin 257 
and 100 mg mL
-1
 streptomycin (GIBCO BRL, Grand Island, NY) enriched with 2 mM 258 
of L-glutamine and 10% of fetal bovine serum (leukemic cells) or 5% (adherent cells). 259 
All cultures were maintained at 37 ºC in a humidified incubator with 5% CO2 and 95% 260 
air. The media was changed twice a week and they were regularly examined. 261 
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2.11.2. Evaluation of the cytotoxic effect against human tumor cell lines 262 
HL60 and Jurkat cells were inoculated at 50,000 and 100,000 cells/well, respectively, 263 
and MDA-MB cells were inoculated at 10,000 cells/well. The plates were pre-incubated 264 
for 24 h at 37 ºC to allow adaptation of cells prior to the addition of the test compounds. 265 
Freshly prepared solutions of the different compounds were tested at 10 μM. 266 
Subsequently, the plates were inoculated for 48 h in 5% CO2 and 100% relative 267 
humidity atmosphere. Control groups included treatment with 0.5% DMSO (negative 268 
control) and 10 μM of cisplatin (positive control). Cell viability was estimated by 269 
measuring the rate of mitochondrial reduction of MTT.
77
 All compounds were dissolved 270 
in DMSO prior to dilution. The optical densities (OD) were evaluated in a 271 
spectrophotometer at 595 nm. Controls included drug-containing medium (background) 272 
and drug-free complete medium. Drug-free complete medium was used as control 273 
(blank) and was treated in the same way as the drug-containing media. Results were 274 
expressed as percentage of cell proliferation, comparing with 0.5% DMSO control and 275 
were calculated as follows: viability (%) = (mean OD treated – mean OD 276 
background)/(mean OD untreated cultured, i.e. 0.5% DMSO – mean OD blank wells) x 277 
100. Interactions of compounds and media were estimated on the basis of the variations 278 
between drug-containing medium and drug-free medium to minimize false-positive or 279 
false-negative readings.
78
 280 
3. Results and discussion 281 
3.1. Synthesis and Characterization 282 
One new acetohydrazone ligand, 8-H2QH, was synthesized by condensation of 283 
acethydrazide with 8-hydroxyquinoline-2-carboxaldehyde (Scheme 1). 8-H2QS and 8-284 
H2QT have been previously prepared.
57-58
 8-H2QH was characterized by elemental 285 
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analysis, which is in agreement with the proposed formula. The infrared spectrum (IR) 286 
of the hydrazone displays an absorption at 1678 cm
-1
, which was assigned to (C=O), 287 
and the absorption at 1594 cm
-1 
was attributed to (C=N) of the iminic bond, confirming 288 
hydrazone formation.
79
 Hydrazones have been reported to exist as tautomeric 289 
enolimines with the speciation dependent on electronic and structural effects, including 290 
inter- and intra-molecular hydrogen bonding.
80-81
 Both the keto and enol forms were 291 
observed by 
1
H NMR and 
13
C NMR for 8-H2QH in solution (Fig. S1). However, the X-292 
ray crystallographic structural analysis indicates that in the solid state this compound 293 
exists only in the keto form.  294 
Insert Scheme 1 295 
3.2. Crystal Structure Determination 296 
The ORTEP diagram of 8-H2QH is shown in Fig. 2. Selected intramolecular bond 297 
lengths and angles, and hydrogen bonding parameters in the structure of 8-H2QH are 298 
given in Tables S1 and S2 (Supporting Information), respectively. 8-H2QH crystalizes 299 
with two independent molecules of the hydrazone (A and B, Fig. S2) per asymmetric 300 
unit. Since the geometrical parameters of the two molecules are similar (see Table 2 and 301 
S1), we will further describe molecule A here. 302 
Insert Fig. 2 303 
In A the C9–N2 and C10–O2 interatomic distances indicate double bond character 304 
(Table 2). The C=N–N–C(=O)C skeleton is almost planar (rms deviation from the least-305 
squares plane of 0.0066 Å). The molecule adopts the EE conformation in relation to the 306 
C9–N2 and N3–C10 bonds, as indicated by the C2–C9=N2–N3, and N2–N3–C10–O2 307 
torsion angles of 179.4(1)
 o
, and 179.1(1)
 o
, respectively. 308 
Insert Table 2 309 
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 In the molecular packing of 8-H2QH various NH⋯O hydrogen bonds forming 310 
centrosymmetric dimers were observed. The NH⋯O and CH⋯O hydrogen bonds (see 311 
parameters in Table S2) involving A and B lead to the formation of an infinite two-312 
dimensional (2D) network (Fig. S3). The low solubility of the compound may be 313 
attributed to these H-bonds as well as to π- π  interactions in the solid state.  314 
3.3. Ligand Speciation Studies 315 
Speciation studies were performed in 5% DMSO in 0.1 M NaCl for 8-H2QH, 8-H2QS 316 
and 8-H2QT in a range of pH varying from 2 to 12. In the pH range evaluated, there are 317 
four possible species (H3L
+
, H2L, HL
-
, L
2-
, where H2L is neutral) as shown in Scheme 2. 318 
Fitting the variable pH UV-Vis data for the compounds affords three pKa values for 319 
each compound (Table 3), with the speciation diagrams shown in Fig. 3. 320 
Insert Table 3 321 
The pKa values for HCQ have been reported as pKa1 3.17 ± 0.11 and pKa2 8.05 ± 0.08  at 322 
25 °C.
82
 The pKa1 refers to the deprotonation of the pyridine nitrogen and pKa2 refers to 323 
deprotonation of the hydroxyl oxygen. The pKa1 values for the 8-hydroxyquinoline 324 
derivatives studied are in accordance with the value reported in the literature for HCQ. 325 
The pKa1 value for 8-H2QH is lower than those measured for 8-H2QS and 8-H2QT. 8-326 
H2QH displays a tautomeric equilibrium in solution (Fig. S1), that increases the 327 
electron-withdrawing effect of the hydrazone moiety on the quinoline scaffold. 328 
Consequently, the quinoline has its mesomeric stabilization also increased.
83
 Electron-329 
withdrawing groups, especially at position 2 of the quinoline, will decrease the electron 330 
density on the ring thus reducing the donating ability of the quinoline nitrogen atom.
84
 331 
The pKa2 values for 8-H2QH, 8-H2QS, and 8-H2QT are higher than the value reported 332 
for HCQ. HCQ has two electron-withdrawing groups in the o- and p- positions (I and 333 
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Cl), which lowers the basicity of the quinoline hydroxyl.
83
 Interestingly, the pKa3 value 334 
for 8-H2QT is significantly less than the values for 8-H2QH and 8-H2QS. We attribute 335 
this difference to the stabilizing effect of the sulfur atom on the dianionic form of 8-336 
H2QT. This stabilizing effect likely plays a role in the different metal:ligand ratio in the 337 
Cu
II
 complex of 8-H2QT in comparison to 8-H2QH and 8-H2QS (vide infra).   338 
Insert Scheme 2 339 
Insert Fig. 3 340 
The logK n-octanol/water values (logPcalc, ALOGPS 2.1 software, Table 3) were 341 
calculated to evaluate the order of Gibbs free energies of solvation. The calculated 342 
values were not statistically different, suggesting equivalent solubility behavior in 343 
physiological fluids for all derivatives. However, evaluation of the absolute values of 344 
logPcalc suggested a trend of hydrophobicity: 8-H2QT > 8-H2QH > 8-H2QS. 8-H2QT 345 
exhibited the lowest aqueous solubility in this work. The calculated values for HCQ are 346 
in accordance with the experimental data.
85
 A similar trend obtained by the same 347 
software was previously validated for other Schiff-bases; the predicted logPcalc values 348 
were similar to the experimental values but statistically different due to lower standard 349 
errors.
86
  350 
3.3. Metal Binding Properties 351 
UV-Vis spectroscopy was used to probe the solution binding of 8-H2QS, 8-H2QH and 352 
8-H2QT with Cu
II
, and compare to the solid state characterization data. Changes in the 353 
intensity of the ligand-based transitions, along with the observation of new absorptions 354 
at ca. 449 nm and 438 nm indicated metal binding to ligand 8-H2QH. Similar shifts of 355 
these peaks for 8-H2QT and 8-H2QS were also observed upon treatment with Cu
II
 356 
indicating metal binding to the ligands. Job plot analysis (Fig. 4) suggests the formation 357 
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of a 1:1 metal:ligand compound for 8-H2QT in agreement with previous reports of 358 
complex formation for this thiosemicarbazone and analogues.
56-57
 Interestingly, a 1:2 359 
metal:ligand ratio was determined for 8-H2QS and 8-H2QH with Cu
II
, matching the 360 
solid-state characterization data for the complexes. The Job plot results, and resulting 361 
metal:ligand stoichiometries in solution, can be correlated to the pKa values for the three 362 
ligands. The high pKa3 values for 8-H2QS and 8-H2QH (>12) suggest lower probability 363 
of deprotonation of the N–H Schiff base moiety leading to preferential formation of 1:2 364 
metal:ligand complexes where only the phenolate has been deprotonated. On the other 365 
hand, the lower pKa3 value for the 8-H2QT derivative leads to an increased stabilization 366 
of the dianionic form, inducing neutral 1:1 metal:ligand complex formation, with a 367 
tetradentate doubly deprotonated ligand. This proposition is in accordance to the 368 
presence of sulfur, a more polarizable atom in comparison to the oxygen atoms that are 369 
present in the 8-H2QS and 8-H2QH frameworks. 370 
Insert Fig. 4 371 
3.4. Theoretical Calculations of the CuII Complexes 372 
We further investigated the Cu
II
 complexes of the 8-hydroxyquinoline ligands by 373 
theoretical calculations. A previously reported X-ray structure of Cu(8-QT) displays a 374 
1:1 ligand:metal stoichiometry,
56
 in accordance with our solution analysis (vide supra). 375 
The optimized geometry of Cu(8-QT) is in good agreement with the experimental 376 
metrical parameters, with coordination sphere bond lengths predicted within  0.06 Å 377 
(Fig. S5 and Table S3). Based on these results we employed the same functional and 378 
basis set to investigate the structures of Cu(8-HQH)2 and Cu(8-HQS)2, and compared 379 
the results to the reported 1:2 metal:ligand structure for Cu(CQ)2.
87
 The X-ray metricals 380 
for Cu(CQ)2 and the computed values are shown in Table 4. The predicted coordination 381 
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sphere metrical parameters for Cu(8-HQH)2, Cu(8-HQS)2, and Cu(CQ)2 are within  382 
0.06 Å of the reported data for Cu(CQ)2.
87
 The computed structure of Cu(8-HQH)2 is 383 
shown in Fig. 5, all other structures are shown in the Supporting Information (Fig. S5-384 
S7). Of interest is the considerable distortion away from a square planar geometry 385 
predicted for both Cu(8-HQH)2 and Cu(8-HQS)2 (dihedral angle = 42 for both 386 
structures)  in comparison to the reported structure for Cu(CQ)2 (dihedral angle = 0).
87
 387 
To further investigate the effects of crystal packing and steric interactions of the o-8-388 
hydroxyquinoline substituents on the dihedral angle we calculated the optimized 389 
geometry of Cu(CQ)2 at the same level of theory. The optimized geometry of Cu(CQ)2 390 
displays a dihedral angle of 17 (Fig. S7) which suggests that while crystal packing 391 
plays a role in flattening the reported Cu(CQ)2 structure, the extended Schiff-base 392 
groups of the 8-H2QH and 8-H2QS ligands likely lead to the large predicted tetrahedral 393 
distortion observed for the corresponding 1:2 metal:ligand complexes.  394 
Insert Fig. 5 395 
Insert Table 4 396 
3.5. Antioxidant Capacity – TEAC Test 397 
Evidence of oxidative stress is widespread in AD, with early neuronal and pathological 398 
changes showing indications of oxidative damage.
88-89
 The brain is particularly 399 
susceptible to oxidative damage due to the high rate of metabolic activity coupled with 400 
relatively low antioxidant levels and low tissue regenerative capacity.
31
 We thus studied 401 
the antioxidant activity of 8-H2QH, 8-H2QS and 8-H2QT via the Trolox Equivalent 402 
Antioxidant Capacity (TEAC) assay.
48, 70, 90
 The ability of the compounds to quench the 403 
ABTS˙+ radical cation was compared to Trolox, a water-soluble analog of ±--404 
tocopherol (Fig. 6). The Schiff-bases exhibited TEAC values that were statistically 405 
equivalent to ±--tocopherol and enhanced in comparison to both PBT2 and HCQ. 406 
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The potent antioxidant properties observed for the Schiff-bases in this test in 407 
comparison to the other hydroxyquinoline derivatives is likely due to the negative 408 
inductive effect of the Cl and I ring substituents in PBT2 and HCQ which decrease the 409 
stability of a hydroxyl radical, reducing the antioxidant properties of these derivatives. 410 
In addition, the increased stabilization of the phenoxyl radical through the extended 411 
conjugation promoted by the semicarbazone, thiosemicarbazone and acetohydrazone 412 
moieties in the Schiff-bases may also contribute to the increased antioxidant properties 413 
of 8-H2QH, 8-H2QS, and 8-H2QT.  414 
Insert Fig. 6 415 
3.6. Inhibition of A Aggregation via Turbidity Measurements  416 
A turbidity test was carried out as a preliminary evaluation of the ability of 8-417 
hydroxyquinoline derivatives to modulate or even suppress the aggregation of the A1-40 418 
peptide induced by Cu
II
, providing information about the extent of peptide aggregation 419 
in solution on a short timescale (45 min). This test is completed by light scattering 420 
measurements at 405 nm.
9, 91
 8-H2QT was not soluble under the test conditions (5% v/v 421 
DMSO in HEPES buffer pH 7.4), in agreement with its absolute logPcalc value which 422 
suggests higher hydrophobicity in comparison to 8-H2QH and 8-H2QS. Therefore, the 423 
turbidity test was carried out for 8-H2QH and 8-H2QS. The pH value was adjusted to pH 424 
6.6 to maximize the Cu
II
-induced aggregation process.
9
 Aggregation induced by Cu
II
 425 
was significantly inhibited by compounds 8-H2QH and 8-H2QS with respect to the 426 
negative control (Cu
II
 and peptide) (Fig. 7). In addition, there was a statistically 427 
significant difference between 8-H2QS and diethylenetriamine pentaacetic acid (DTPA, 428 
positive control) with respect to aggregation, suggesting that this derivative exhibits a 429 
greater inhibitory activity than the positive control under the test conditions; 8-H2QH, 430 
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exhibits similar aggregation inhibition in comparison to DTPA. The higher anti-431 
aggregating effect displayed by 8-H2QS in comparison to 8-H2QH in this test may be 432 
attributed to its higher hydrophilicity in comparison to 8-H2QH (suggested by logPcalc 433 
values), increased H-bonding interactions of the carboxamide function, and / or 434 
differences in the tautomeric ratio of the Schiff bases under the assay conditions. 435 
Insert Fig.7 436 
3.7. Monitoring A Aggregation via Native Gel Electrophoresis and Western 437 
Blotting  438 
It is possible to obtain a more detailed picture of the extent and pathways of A 439 
aggregation by using native gel electrophoresis, Western blotting, and TEM analysis 440 
techniques. The lower molecular weight, soluble A species can be visualized by native 441 
gel electrophoresis and Western blotting, while higher molecular weight and insoluble 442 
A aggregates can be revealed by TEM analysis.22 The aggregation process of the more 443 
neurotoxic and oligomer-forming
92-94
Apeptide was probed by these 444 
aforementioned techniques in the presence of the 8-hydroxyquinoline compounds and 445 
Cu
II
. Native gel electrophoresis and Western blotting and the corresponding TEM 446 
images are shown in Fig. 8. Awas used at 25 M for all the samples. Lane 2 447 
contains A only, while Lanes 4, 6 and 8 contain Ain the presence of 8-H2QH, 448 
8-H2QS, and PBT2 respectively. The pattern of Aaggregation does not change in 449 
the presence of 3 equiv. of the ligands showing that the ligands alone do not influence 450 
the aggregation process in this assay over 24 hrs. The pattern of Aaggregation in 451 
the presence of Cu
II
 (1 equiv.) shows reduced aggregate formation (Lane 3), in 452 
accordance with prior reports of Cu
II
-induced oligomer formation.
22, 24
 Lanes 5, 7, and 9 453 
contain, additionally to Aand Cu
II
, the ligands 8-H2QH, 8-H2QS and, PBT2 454 
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respectively. The addition of 8-H2QH, 8-H2QS, or PBT2 alters the pattern of 455 
aggregation to match that of A only (Lane 2). These results suggest that the ligands 456 
sequester Cu
II
, likely restricting the formation of Cu
II
-containing oligomers in this 457 
assay. The TEM images are in accordance with the Gel assay, showing large molecular 458 
weight aggregates for all Lanes except Lane 3 (A and Cu
II
). Interestingly, the gel 459 
assay for PBT2 (Lane 9) visually shows less large molecular weight aggregates in 460 
comparison to both 8-H2QH (Lane 5) and 8-H2QS (Lane 7) suggesting that PBT2 does 461 
not inhibit Cu
II
-A peptide interactions to the same extent as the 8-H2QX series. 462 
While particle size analysis by TEM shows a range in sizes, certain trends are observed 463 
in the data. The Aonly particle size range (0.12 – 68.99 m
2
) by TEM analysis is 464 
larger than A in the presence of Cu
II
 (0.11 – 1.12 m2), in accordance with the gel 465 
assay. Ain the presence of Cu
II
 and 8-H2QH (as an example ligand) shows 466 
increased particle size (0.10 – 51.88 m2) in comparison to Aand Cu
II
, with data 467 
similar to Aalone. Full particle size analysis data is presented in Table S4. 468 
Insert Fig. 8 469 
3.8. Cytotoxic activity  470 
For the treatment of AD, to avoid undesirable side-effects, the compounds should 471 
demonstrate low cytotoxicity. We investigated the preliminary cytotoxicity of 8-H2QS 472 
and 8-H2QH in the MDA-MB, HL60, and Jurkat human tumor cell lines. A preliminary 473 
screen (10 M) of both compounds displayed very low cytotoxicity as measured by a 474 
MTT assay. 475 
Insert Table 5 476 
4. Summary 477 
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In the present work we synthesized and characterized a new acetohydrazone (8-H2QH) 478 
derived from 8-hydroxyquinoline, its Cu
II
 complex and also the Cu
II
 complex of 8-479 
hydroxyquinoline semicarbazone (8-H2QS), as part of the evaluation of new metal-480 
protein attenuating compounds (MPAC) as Alzheimer’s disease (AD) therapeutics. The 481 
solution speciation (pKa values) suggest suitable physicochemical properties (neutral, 482 
water soluble) for CNS-targeting compounds, and the metal:ligand binding studies 483 
demonstrated the ability of the ligands to bind Cu
II
, under physiological conditions. The 484 
antioxidant capacity of these ligands was tested, along with drug candidates PBT2 and 485 
HCQ. 8-H2QH and 8-H2QS displayed significantly higher antioxidant capacity when 486 
compared to PBT2 and HCQ. The chelating abilities of the Schiff-bases and their 487 
subsequent effects on amyloid- peptide aggregation were evaluated. An initial 488 
turbidity assay with A was used to evaluate the influence of the ligands on the 489 
short-term Cu
II
-induced aggregation of the peptide. 8-H2QS, 8-H2QH and DTPA 490 
(positive control) each presented a statistically significant decrease in aggregation in 491 
comparison to the negative control, A in the presence of Cu
II
. Native gel 492 
electrophoresis/Western blotting and TEM images were used to evaluate the influence 493 
of the Schiff-base ligands and PBT2 on the aggregation of A both in the presence 494 
and absence of Cu
II
. The Western blotting showed that the pattern of Aaggregation 495 
in the presence of 8-H2QH, 8-H2QS, and PBT2 was similar to that of peptide only. The 496 
TEM results were in accordance with these observations. A in the presence of Cu
II
 497 
showed a different pattern of aggregation, exhibiting the presence of oligomers (<15 498 
KDa), while high molecular weight aggregates (>130 KDa) were inhibited. In the 499 
presence of 8-H2QH or 8-H2QS, and Cu
II
 the pattern of aggregation was similar to 500 
peptide only, suggesting that the Schiff-base ligands limit Cu
II
-induced oligomer 501 
formation via metal complexation. A similar result was observed for PBT2, however 502 
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less high molecular weight aggregates were observed suggesting that this derivative 503 
does not restrict Cu
II
-induced oligomer formation to the same extent as 8-H2QH and 8-504 
H2QS in this assay. In summary, 8-H2QH and 8-H2QS were found to influence metal-505 
induced A aggregation and exhibit antioxidant capacity similar to vitamin E. Overall, 506 
the 8-hydroxiquinoline derivatives show promise for modulating metal-Apeptide 507 
interactions. 508 
Abbreviations:  509 
8-H2QH 2-[(8-Hydroxyquinolinyl)methylene]acetohydrazide 
8-H2QS 2-[(8-Hydroxyquinolinyl)methylene]hydrazinecarboxamide 
8-H2QT 2-[(8-Hydroxyquinolinyl)methylene]hydrazinecarbothioamide 
HQC 5-chloro-7-iodo-8-hydroxyquinoline (Clioquinol) 
TEAC Trolox Equivalent Antioxidant Capacity 
TEM Transmission Electron Microscopy 
PBT2 5,7-dichloro-2-((dimethylanimo)methyl)quinolin-8-ol 
ROS reactive oxygen species 
MPAC Metal-Protein Attenuating Compounds 
BBB Blood-Brain Barrier 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
DFT Density Functional Theory 
ABTS 2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid 
DTPA Diethylene triamine pentaacetic acid 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
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Figure 1.  Chemical structures of 2-[(8-Hydroxyquinolinyl)methylene]acetohydrazide 
(8-H2QH), 2-[(8-Hydroxyquinolinyl)methylene]hydrazinecarboxamide (8-H2QS), 2-[(8-
Hydroxyquinolinyl)methylene]hydrazinecarbothioamide (8-H2QT), Clioquinol (HCQ), 
PBT2, and Triapine. 
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Table 1. Crystal structure and refinement data for 8-H2QH. 
Compound 8-H2QH 
Empirical Formula C12H11N3O2 
Formula Weight 229.24 
Temperature, K 150(2)  
Wavelength, Å 0.71073 
Crystal System Triclinic 
Space Group Pī 
Unit cell dimensions 
a, Å 8.6542(2) 
b, Å 10.2904(4) 
c, Å 12.6933(4) 
, º 72.860(3) 
, º 83.873(2) 
, º 87.479(2) 
Volume, Å
3
 1073.94(6) 
Z / Density calc., Mg/m
3
 4 / 1.418 
Absorption coefficient, mm
–1
 0.100 
Reflection collect. / 
 unique [Rint] 
23880/ 
4390 [R(int) = 0.0268] 
Goodness–of–fit on F2 1.055 
R indices (all data) R1 = 0.0363, wR2 = 0.1005 
Final R indices [I>2(I)] R1 = 0.0423, wR2 = 0.1079 
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Scheme 1. Synthesis of 8-H2QH. The keto form is shown. 
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Figure 2. ORTEP diagram for 8-H2QH with thermal ellipsoids at the 50% probability 
level. Hydrogen atoms are drawn as circles of arbitrary radii. 
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Table 2. Selected bond lengths (Å) and torsion angles (
o
) for the 8-H2QH structure. 
Bond (Å) Angles (
o
) 
N1–C2 1.328(2) O1–C8–C8A 118.0(1) 
C2–C9 1.464(2) C8–C8A–N1 116.5(1) 
C9–N2 1.280(2) N1–C2–C9 115.7(1) 
N2–N3 1.363(2) C2–C9–N2 119.8(1) 
N3–C10 1.358(2) C9–N2–N3 116.5(1) 
C10–O2 1.230(2) N2–N3–C10 120.3(1) 
C10–C11 1.503(2) N3–C10–O2 119.8(1) 
C8–O1 1.358(2) N3–C10–C11 122.9(1) 
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Table 3. pKa and logPcalc values of compounds 8-H2QT, 8-H2QH and 8-H2QS. pKa data 
were analyzed using the HypSpec program (Protonic Software, UK), and logPcalc was 
calculated using ALOGPS 2.1 software.
95,96
 
Compound pKa1 pKa2 pKa3 logPcalc logPexp 
8-H2QT 3.36 ± 0.01 9.51 ± 0.01 11.75 ± 0.01 1.67 ± 0.31 - 
8-H2QH 2.87 ± 0.03 9.53 ± 0.03 13.50 ± 0.01 1.62 ± 0.58 - 
8-H2QS 3.25 ± 0.02 9.63 ± 0.01 13.16 ± 0.01 1.12 ± 0.29 - 
HCQ
a 
3.17 ± 0.11 8.05 ± 0.08   - 3.43 ± 0.21 3.24
a 
 a
[82]
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Scheme 2. Protonation states of the 8-hydroxyquinoline Schiff-base ligands.  
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Figure 3. Speciation diagrams of 8-H2QT (A), 8-H2QH (B) and 8-H2QS (C). 
FL = fraction of species. H2L = neutral species. Diagrams were simulated using the 
HySS2009 program (Protonic Software, UK). 
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Figure 4. Job plots of 8-H2QS (▼ / Δ 420 nm), 8-H2QH ( /  449 nm) and 8-H2QT 
( /  404 nm) with copper acetate (20% DMSO in HEPES buffer pH 7.4). The 
dashed lines for 8-H2QH (Cu
II
) and 8-H2QS (Cu
II
) indicate a 1:2 
Cu
II
:L stoichiometry. The dashed line for 8-H2QT (Cu
II
) indicates a 1:1 Cu
II
:L 
stoichiometry.   
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Figure 5. DFT-optimized geometry of Cu(8-HQH)2 displaying a distorted square planar 
geometry with a metal coordination sphere torsion angle of 47
o
. See Experimental 
Section for calculation details.  
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Table 4. Comparison of experimental (Cu(CQ)2) and calculated (Cu(8-HQH)2, Cu(8-
HQS)2, Cu(CQ)2) coordination sphere bond lengths. See Experimental Section for 
calculation details. 
 Experimental (Å)
a
 Predicted Bond Lengths (Å) 
 Cu(CQ)2 Cu(CQ)2 Cu(8-HQH)2 Cu(8-HQS)2 
Cu – N1 1.984 1.969 2.016 2.017 
Cu – N2 1.963 1.969 2.016 2.017 
Cu – O1 1.915 1.904 1.888 1.887 
Cu – O2 1.923 1.904 1.888 1.887 
a
[87] 
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Figure 6. Trolox Equivalent Antioxidant Capacity (TEAC) values at 1, 3, and 6 min for 
()--tocopherol, PBT2, Clioquinol (HCQ), 8-H2QH, 8-H2QS and 8-H2QT. Error bars 
represent  SD above and below the average TEAC value (determined in triplicate). 
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Figure 7. Degree of A1–40 aggregation as measured by UV-Vis measurements. Data 
represent the mean absorbance of quadruplicate trials at 405 nm of peptide in the 
presence of Cu
II
 ions, and Cu
II
 and ligands at pH 6.6. Error bars represent  SD above 
(and below not shown) the average absorbance value. 
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Figure 8. Native Gel/Western blots and TEM images of A1–42 aggregation 
experiments. Top: (1) protein reference; (2) A1–42; (3) A1–42 + Cu
II
; (4) A1–42 + 8-
H2QH (3 equiv); (5) A1–42 + Cu
II
 + 8-H2QH (3 equiv); (6) A1–42 + 8-H2QS (3 equiv);  
(7) A1–42 + Cu
II
 + 8-H2QH (3 equiv); (8) A1–42 + PBT2 (3 equiv); (9) A1–42 + Cu
II
 + 
PBT2 (3 equiv); bottom: TEM images of the same samples. Conditions: 24 hours with 
agitation in PBS at 37 °C, [A] = [M] = 25 M. The scale bar in each TEM image 
represents 200 nm. 
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Table 5. Cytotoxic activities of 8-H2QH and 8-H2QS compounds against human cell 
lines. 
Cell Line % Inhibition of cell / viability proliferation 
 8-H2QS 8-H2QH Cisplatin 
MDA-MB 8.3 ± 2.1 Inactive  21.2 ±5.1 
HL60 Inactive 7.0 ± 3.2 90.3 ± 1.4 
Jurkat Inactive  4. ±2.2 86.6 ± 6.2 
 
